|View printer-friendly version|
|U.S. Physician Surpasses 1,000 Procedures Using Stereotaxis Niobe(R) System|
"I rely on the Niobe system implicitly for my complex EP procedures," said Dr. Burkhardt, who primarily treats complex arrhythmias and is considered an expert in the ablation of VT (ventricular tachycardia) and other complex arrhythmias. "At St. David's, we maintain a high standard of excellence and are committed to employing the most state-of-the-art tools to improve the quality of life for our patients.
Under the leadership of Executive Medical Director Dr.
Dr. Natale, Dr. Burkhardt, and the rest of the TCAI team are at the forefront of advancing treatment for cardiac arrhythmias and are looked to as trusted advisors by EP physicians from around the world. In addition to the numerous clinical studies previously released by TCAI on the effectiveness of
The core components of
This press release includes statements that may constitute "forward-looking" statements, usually containing the words "believe", "estimate", "project", "expect" or similar expressions. Forward-looking statements inherently involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Factors that would cause or contribute to such differences include, but are not limited to, the Company's ability to raise additional capital on a timely basis and on terms that are acceptable, its ability to continue to manage expenses and cash burn rate at sustainable levels, its ability to continue to work with lenders to extend, repay or refinance indebtedness on acceptable terms, continued acceptance of the Company's products in the marketplace, the effect of global economic conditions on the ability and willingness of customers to purchase its systems and the timing of such purchases, competitive factors, changes resulting from the recently enacted healthcare reform in the U.S., including changes in government reimbursement procedures, dependence upon third-party vendors, timing of regulatory approvals, and other risks discussed in the Company's periodic and other filings with the
CONTACT: STXS Company Contact: